Company Overview of Zoetis Inc.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the United States and internationally. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, inc...
10 Sylvan Way
Parsippany, NJ 07054
Founded in 1952
Key Executives for Zoetis Inc.
Chief Executive Officer and Director
Total Annual Compensation: $1.1M
President of International Operations and Executive Vice President
Total Annual Compensation: $558.9K
President of US Operations and Executive Vice President
Total Annual Compensation: $625.5K
President of Research & Development and Executive Vice President
Total Annual Compensation: $499.6K
Compensation as of Fiscal Year 2015.
Zoetis Inc. Key Developments
Zoetis Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016; Provides Earnings Guidance for the Year 2017
Feb 16 17
Zoetis Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2016. For the quarter, the company reported revenue of $1,277 million compared to $1,274 million a year ago. Income before provision for taxes on income was $231 million compared to $69 million a year ago. Net income attributable to the company was $154 million or $0.31 per basic and diluted share compared to $22 million or $0.04 per basic and diluted share a year ago. Non-GAAP adjusted net income attributable to the company was $232 million or $0.47 per diluted share compared to $214 million or $0.43 per diluted share a year ago.
For the year, the company reported revenue of $4,888 million compared to $4,765 million a year ago. Income before provision for taxes on income was $1,228 million compared to $545 million a year ago. Net income attributable to the company was $821 million or $1.65 per diluted share compared to $339 million or $0.68 per basic and diluted share a year ago. Non-GAAP adjusted net income attributable to the company was $975 million or $1.96 per diluted share compared to $889 million or $1.77 per diluted share a year ago. Adjusted net income for full year 2016 excludes the net impact of $154 million for purchase accounting adjustments, acquisition-related costs and certain significant items.
The company provided earnings guidance for the year 2017. For the year, the company expects revenue of $5,100 million to $5,225 million, operational growth of 5.5% to 7.5%, adjusted EBIT margin of 34% to 35%, effective tax rate on adjusted income of approximately 30%, adjusted diluted EPS of $2.26 to $2.36, adjusted net income of $1,120 million to $1,170 million. Reported diluted EPS for the full year expects to be $2.08 to $2.20 per share.
Zoetis Inc. Declares Second Quarter 2017 Dividend, Payable on June 1, 2017
Feb 14 17
The Board of Directors of Zoetis Inc. has declared a second quarter 2017 dividend payable to holders of the company’s common stock of $0.105 per share. The dividend is to be paid on June 1, 2017, to holders of record on April 6, 2017.
Anatara Lifesciences Receives Second Payment Under the Exclusive Evaluation and License Option Agreement with Zoetis Inc
Jan 29 17
Anatara Lifesciences has announced that it has received a second payment under the exclusive Evaluation and License Option Agreement with the leading global animal health company Zoetis Inc. for Detach, Anatara's non-antibiotic anti-infective product. Under terms of the agreement which was initially announced on the 18th January 2016, Zoetis has exclusive rights to evaluate the potential applications of DetachTM for veterinary use in food production animals. Anatara has granted Zoetis an option to license DetachTM for development and commercialization in markets worldwide while retaining rights to the Australian and New Zealand markets. The companies agreed on a research program for investigation of the utility in multiple livestock species during the option period.
Similar Private Companies By Industry
Recent Private Companies Transactions